Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Interferon beta is the first-line treatment for relapsing-remitting multiple sclerosis, but the drug can induce neutralising antibodies against itself, which might reduce effectiveness. We aimed to assess the clinical effect of neutralising antibodies.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Lancet |
Vol/bind | 362 |
Udgave nummer | 9391 |
Sider (fra-til) | 1184-91 |
Antal sider | 8 |
ISSN | 0140-6736 |
DOI | |
Status | Udgivet - 11 okt. 2003 |
ID: 34102049